In last trading session, BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) saw 6.09 million shares changing hands with its beta currently measuring 2.50. Company’s recent per share price level of $16.15 trading at -$0.54 or -3.24% at ring of the bell on the day assigns it a market valuation of $3.12B. That closing price of BCRX’s stock is at a discount of -14.43% from its 52-week high price of $18.48 and is indicating a premium of 51.08% from its 52-week low price of $7.90. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 6.46 million shares which gives us an average trading volume of 3.40 million if we extend that period to 3-months.
For BioCryst Pharmaceuticals Inc. (BCRX), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 2.10. Splitting up the data highlights that, out of 13 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 10 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.31 in the current quarter.
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) trade information
Upright in the red during last session for losing -3.24%, in the last five days BCRX remained trading in the green while hitting it’s week-highest on Tuesday, 01/11/22 when the stock touched $16.15 price level, adding 6.92% to its value on the day. BioCryst Pharmaceuticals Inc.’s shares saw a change of 16.61% in year-to-date performance and have moved 30.03% in past 5-day. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) showed a performance of 41.29% in past 30-days. Number of shares sold short was 26.08 million shares which calculate 10.15 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $20.33 to the stock, which implies a rise of 20.56% to its current value. Analysts have been projecting $13.00 as a low price target for the stock while placing it at a high target of $30.00. It follows that stock’s current price would drop -85.76% in reaching the projected high whereas dropping to the targeted low would mean a gain of 19.5% for stock’s current value.
BioCryst Pharmaceuticals Inc. (BCRX) estimates and forecasts
Statistics highlight that BioCryst Pharmaceuticals Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added 3.46% of value to its shares in past 6 months, showing an annual growth rate of -15.60% while that of industry is 16.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 8.80% in the current quarter and calculating 13.90% increase in the next quarter. This year revenue growth is estimated to rise 784.90% from the last financial year’s standing.
11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $47.96 million for the same. And 3 analysts are in estimates of company making revenue of $47.99 million in the next quarter that will end on Mar 2022. Company posted $4.02 million and $8.89 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 1,094.20% while estimating it to be 439.80% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -13.10% during past 5 years. In 2022, company’s earnings growth rate is likely to be around -16.00% while estimates for its earnings growth in next 5 years are of 17.10%.
BioCryst Pharmaceuticals Inc. is more likely to be releasing its next quarterly report between February 23 and February 28 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s Major holders
Insiders are in possession of 1.19% of company’s total shares while institution are holding 59.22 percent of that, with stock having share float percentage of 59.93%. Investors also watch the number of corporate investors in a company very closely, which is 59.22% institutions for BioCryst Pharmaceuticals Inc. that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at BCRX for having 15.33 million shares of worth $220.3 million. And as of Sep 29, 2021, it was holding 8.57% of the company’s outstanding shares.
The second largest institutional holder is Baker Brothers Advisors, LLC, which was holding about 12.71 million shares on Sep 29, 2021. The number of shares represents firm’s hold over 7.11% of outstanding shares, having a total worth of $182.65 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 29, 2021, the former fund manager was holding 5.07 million shares of worth $72.87 million or 2.84% of the total outstanding shares. The later fund manager was in possession of 4.13 million shares on Oct 30, 2021, making its stake of worth around $61.6 million in the company or a holder of 2.31% of company’s stock.